One of the biggest problems in cancer treatment today is the development of resistance to targeted therapies. Victor Velculescu, MD, PhD, and colleagues looked at tumors from patients with metastatic colorectal cancer to find out why some are resistant to a particular targeted treatment. They found a number of genetic changes in the resistant tumors and, based on that information, tested new drug combinations that overcame the drug resistance in laboratory tests. The hope now is to take this approach into the clinic so that doctors can select the right combination of drugs based on the genetic makeup of individual patients’ tumors. Dr. Velculescu is co-leader of the
SU2C-Dutch Cancer Society Dream Team on Molecular Early Detection of Colorectal Cancer and served as a principal on the SU2C Pancreatic Cancer Dream Team that just finished its grant term earlier this year.